• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE)

byConstance Wu
October 31, 2019
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

Neoadjuvant dostarlimab is a promising treatment option in locally advanced dMMR rectal cancer

Adherence to pre-treatment imaging guidelines for staging in rectal cancer is increasing, but a gap still remains

S-1 plus oxaliplatin noninferior to fluorouracil, leucovorin, and oxaliplatin in perioperative chemotherapy for locally advanced gastric cancer: FOCUS trial

1. Adjuvant FOLFOX improves disease-free survival in patients with pathologic Stage II or III rectal cancer after upfront surgery and preoperative chemoradiotherapy, but is associated with a higher rate of adverse events.

Evidence Rating Level: 1 (Excellent)

Postoperative pathologic stage is one of the most important prognostic factors in patients with rectal cancer after surgery and preoperative chemoradiotherapy (CRT). Adjuvant chemotherapy is also recommended after surgery for patients with postoperative pathologic stages II and III rectal cancer. And, although only adjuvant fluoropyrimidines have demonstrated a survival benefit, oxaliplatin-based regimens are widely used in this setting based on the extrapolation of results from patients with colon cancer. In addition, most previous studies of oxaliplatin-based regimens have been designed based on clinical rather than pathologic staging. In this multicenter, randomized, controlled trial, 321 patients with postoperative ypStage II (ypT3-4N0) or III (ypTanyN1-2) rectal cancer after fluoropyrimidine-based preoperative CRT and total mesorectal excision (TME) were randomized to receive adjuvant chemotherapy with either fluorouracil and leucovorin (FL) or FOLFOX (oxaliplatin, leucovorin, and fluorouracil) to study disease-free survival (DFS). Researchers found that at 6 years of follow-up, the DFS rate was higher in the FOLFOX group than in the FL group (68.2% vs. 56.8%, respectively, HR 0.63, 95% CI 0.43 to 0.93, p=0.018). There was no statistically significant difference in 6-year overall survival (OS) between the two groups (FOLFOX 78.1% vs. FL 76.4%, HR 0.73, 95% CI 0.45 to 1.19, p=0.21). Exploratory subgroup analysis of DFS also revealed that FOLFOX treatment was favorable compared with FL in patients with ypStage III disease, male gender, age younger than 65 years, advanced pathologic stages, high-grade histology, minimally regressed tumor, an absence of lymphovascular or perineural invasion, and a longer than 6-week interval between CRT and surgery. Neutropenia (69.9% vs. 45.6%, p<0.001) and thrombocytopenia (26.0% vs. 2.0%, p<0.001) were, however, more common in the FOLFOX group, as were fatigue (28.3% vs. 17.4%, p=0.037), nausea (53.4% vs. 37.6%, p=0.007), and sensory neuropathy (70.5% vs. 5.4%, p<0.001); however, there was no significant difference in the occurrence of grade 3 or 4 adverse events between the two groups. Overall, this study suggests that adjuvant FOLFOX may improve disease-free survival in patients with postoperative ypStage II or III rectal cancer who received preoperative CRT and TME, but is associated with a higher rate of adverse events.

Click to read the study in the Journal of Clinical Oncology

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: chemoradiationFOLFOXoxiplatinrectal cancer
Previous Post

Screening for vaccine hesitancy not associated with decreased under-immunized time

Next Post

The ORIP trial: n-3 polyunsaturated long chain fatty acid supplementation has no effect on preterm delivery rate

RelatedReports

Patient Basics: Anal Disorders
Oncology

Neoadjuvant dostarlimab is a promising treatment option in locally advanced dMMR rectal cancer

June 13, 2022
Radiofrequency ablation of hepatic metastases in colorectal cancer linked with improved survival
Oncology

Adherence to pre-treatment imaging guidelines for staging in rectal cancer is increasing, but a gap still remains

April 4, 2022
Single-cycle adjuvant chemotherapy may be effective in stage I testicular cancer
Chronic Disease

S-1 plus oxaliplatin noninferior to fluorouracil, leucovorin, and oxaliplatin in perioperative chemotherapy for locally advanced gastric cancer: FOCUS trial

March 1, 2022
#VisualAbstract: Positron emission tomography effective at assessing early tumor response to induction chemotherapy in esophageal or esophagogastric junction cancers
StudyGraphics

#VisualAbstract: Positron emission tomography effective at assessing early tumor response to induction chemotherapy in esophageal or esophagogastric junction cancers

December 12, 2021
Next Post
Wide international variation in survival for periviable neonates

The ORIP trial: n-3 polyunsaturated long chain fatty acid supplementation has no effect on preterm delivery rate

#VisualAbstract: Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome

#VisualAbstract: Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome

Quick Take: Prevalence and Treatment of Depression, Anxiety, and Conduct Problems in US Children

Association between parental income during childhood and risk of schizophrenia later in life

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force
  • RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection
  • Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.